CELLCEUTRIX AND DR. MENON, THE OVERVIEW
The way I see Cellceutix is a holding company for Dr Menon's recently developed pharmaceuticals.
Dr Menon has a long history of scientific achievement including developing several "blockbuster" drugs at Eli Lilly. Dr Menon has developed 8 unique compounds including Kevetrin and Prurisol. The initial work was self funded and performed in Dr Menon's lab, Kard Scientific.
In 2007 Dr Menon joined with Eli Ehrlich to form Cellceutix. Cellceutix was given the exclusive rights to Dr Menon's 8 compounds in exchange for a controlling interest in the company. Currently the 2 principals own about 72% of the company.
Cellceutix is responsible for navigating the compounds through the regulatory process. The goal is to achieve full approval and licensing for the compounds. The potential market for the compounds is enormous. Many here think a buyout will occur, but the company's structure may allow it to remain independent.
Cellceutix's anti-psoriasis drug,Prurisol, is furtherest along the regulatory process. It will soon begin phase 2/3 FDA studies. It has also begun the European Union's drug review process.
Kevetrin is in phase 1 FDA studies. In animal studies Kevetrin showed efficacy against a number of solid cancers. Its mechanism of action in animals was activation of P53 and P21, protiens which control the replication of DNA. These proteins have been described as the Human Genome's Guardian Angel genes. Kevetrin's animal studies have resulted in positive effects on reducing tumor growth with no reported toxicity. In addition to repairing DNA they help control cell growth and induce apoptosis of old or abnormal cells.
Kevetrin is also being studied with Pfizer's agents to treat melanoma and renal cell cancer. Kevetrin will be a part of a multidrug European trial to treat leukemia.
Dr Menon's efforts have resulted in Cellceutix being much further along the regulatory process with little dilution and a relatively small number of shares. The small "float" is partly responsible for the recent jump in share price. Cellceutrix also has secured very attractive financing from Aspire
While it is true the company is very small, its value to shareholders is increased due to the chance to own a relatively large part of a dynamic pharmaceutical company.
What some describe as risk others view as opportunity. It is easy to visualize the company's potential.
See Cellceutix's web site for additional information.
Good luck,Farrell
Cellceutix Corporation (CTIX) Stock Trading Info:
AI
